Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 3;99(5):1163-1171.
doi: 10.1016/j.ajhg.2016.08.023. Epub 2016 Oct 13.

Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy

Collaborators, Affiliations

Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy

Luca Bello et al. Am J Hum Genet. .

Abstract

The expressivity of Mendelian diseases can be influenced by factors independent from the pathogenic mutation: in Duchenne muscular dystrophy (DMD), for instance, age at loss of ambulation (LoA) varies between individuals whose DMD mutations all abolish dystrophin expression. This suggests the existence of trans-acting variants in modifier genes. Common single nucleotide polymorphisms (SNPs) in candidate genes (SPP1, encoding osteopontin, and LTBP4, encoding latent transforming growth factor β [TGFβ]-binding protein 4) have been established as DMD modifiers. We performed a genome-wide association study of age at LoA in a sub-cohort of European or European American ancestry (n = 109) from the Cooperative International Research Group Duchenne Natural History Study (CINRG-DNHS). We focused on protein-altering variants (Exome Chip) and included glucocorticoid treatment as a covariate. As expected, due to the small population size, no SNPs displayed an exome-wide significant p value (< 1.8 × 10-6). Subsequently, we prioritized 438 SNPs in the vicinities of 384 genes implicated in DMD-related pathways, i.e., the nuclear-factor-κB and TGFβ pathways. The minor allele at rs1883832, in the 5'-untranslated region of CD40, was associated with earlier LoA (p = 3.5 × 10-5). This allele diminishes the expression of CD40, a co-stimulatory molecule for T cell polarization. We validated this association in multiple independent DMD cohorts (United Dystrophinopathy Project, Bio-NMD, and Padova, total n = 660), establishing this locus as a DMD modifier. This finding points to cell-mediated immunity as a relevant pathogenetic mechanism and potential therapeutic target in DMD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Manhattan Plot of Exome Chip Associations with Age at Loss of Ambulation Additive genotype p values of the Cox proportional-hazards model, with glucocorticoid treatment as a covariate, are shown for 27,025 Exome Chip SNPs with MAF > 0.05. SNPs within, or <10,000 kb upstream or downstream of, prioritized genes in the NF-κB and TGFβ pathways are highlighted in green. The red horizontal line (p = 1.8 × 10−6) refers to Bonferroni correction for 27,025 SNPs, and the blue line (p = 1.1 × 10−4) refers to Bonferroni correction for 438 SNPs within prioritized genes. Top p values are annotated with corresponding gene names (also see Table 1).
Figure 2
Figure 2
Kaplan-Meier Plots of Age at Loss of Ambulation by CD40 rs1883832 Genotype Kaplan-Meier curves are shown (additive and dominant genotype models) in the CINRG Exome Chip cohort and validation cohorts. Abbreviations are as follows: add, additive inheritance model; dom, dominant inheritance model. The overall validation cohort is the sum of CINRG validation, Bio-NMD, Padova, and UDP cohorts.

References

    1. Hoffman E.P., Brown R.H., Jr., Kunkel L.M. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–928. - PubMed
    1. Hoffman E.P., Kunkel L.M., Angelini C., Clarke A., Johnson M., Harris J.B. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology. 1989;39:1011–1017. - PubMed
    1. Humbertclaude V., Hamroun D., Bezzou K., Bérard C., Boespflug-Tanguy O., Bommelaer C., Campana-Salort E., Cances C., Chabrol B., Commare M.C. Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur. J. Paediatr. Neurol. 2012;16:149–160. - PubMed
    1. Jimenez C., Moreno, Eagle M., Mayhew A., James M., Straub V., Bushby K. Impact of three decades of improvement in standards of care for Duchenne muscular dystrophy. Neuromusc Dis. 2015;25:S201–S202.
    1. Pegoraro E., Hoffman E.P., Piva L., Gavassini B.F., Cagnin S., Ermani M., Bello L., Soraru G., Pacchioni B., Bonifati M.D., Cooperative International Neuromuscular Research Group SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology. 2011;76:219–226. - PMC - PubMed

MeSH terms